iRadimed Corp. (NASDAQ:IRMD)’s share price traded down 3.7% during mid-day trading on Monday . The stock traded as low as $17.11 and last traded at $17.73, with a volume of 148,744 shares trading hands. The stock had previously closed at $18.42.

Several equities analysts recently issued reports on the stock. Roth Capital reissued a “buy” rating on shares of iRadimed Corp. in a report on Tuesday, May 3rd. Zacks Investment Research lowered shares of iRadimed Corp. from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 5th.

The stock has a market cap of $189.69 million and a price-to-earnings ratio of 25.29. The stock has a 50-day moving average of $20.24 and a 200-day moving average of $18.43.

iRadimed Corp. (NASDAQ:IRMD) last posted its quarterly earnings results on Friday, July 29th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.03. During the same period last year, the company earned $0.16 EPS. The firm earned $9.90 million during the quarter, compared to analysts’ expectations of $9.60 million. The business’s quarterly revenue was up 30.3% on a year-over-year basis. On average, equities research analysts anticipate that iRadimed Corp. will post $0.92 EPS for the current fiscal year.

In other news, Director Monty K. Allen sold 2,100 shares of the stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $20.44, for a total value of $42,924.00. Following the completion of the sale, the director now owns 4,375 shares of the company’s stock, valued at approximately $89,425. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Monty K. Allen sold 2,275 shares of the stock in a transaction that occurred on Tuesday, June 14th. The shares were sold at an average price of $20.00, for a total transaction of $45,500.00. The disclosure for this sale can be found here.

An institutional investor recently raised its position in iRadimed Corp. stock. GSA Capital Partners LLP boosted its stake in shares of iRadimed Corp. (NASDAQ:IRMD) by 174.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 50,203 shares of the company’s stock after buying an additional 31,901 shares during the period. GSA Capital Partners LLP owned approximately 0.45% of iRadimed Corp. worth $1,407,000 as of its most recent filing with the SEC.

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.